Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Next Previous
Trial Profile

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin; Everolimus
  • Indications Acute coronary syndromes; Coronary artery disease; Myocardial infarction; Stroke
  • Focus Adverse reactions
  • Acronyms TWILIGHT; TWILIGHT-ACS

    • Most Recent Events

    • 29 Aug 2022 Results (N=7119) of prespecified analysis of TWILIGHT study assessing impact of different antiplatelet therapy cessation patterns on ischemic and bleeding outcomes in patients treated with ticagrelor with or without aspirin after percutaneous coronary intervention (PCI) presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
    • 29 Aug 2022 Results (N=7119) of sub analysis using the TWILIGHT patient database developing separate models to predict the risk of bleeding and ischemic events and assess treatment effect of ASA discontinuation across risk strata, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
    • 04 Apr 2022 Results of a post hoc analysis assessing the benefits of discontinuation after 3 months of aspirin plus ticagrelor reduces bleeding without increasing ischemic events in reducing bleeding are preserved across different risk strata presented at the 71st Annual Scientific Session of the American College of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top